Welcome!

News Feed Item

Global Pharmaceutical & Biotechnology Outlook 2014: Japan Pharma

MUMBAI, India, February 11, 2014 /PRNewswire/ --

Bharat Book Bureau presents Global Pharmaceutical & Biotechnology Outlook 2014: Japan Pharma. 2014 will be marked as a transition year for the Japanese Pharma industry - the year is bound to be painful both for innovators and generic companies due to the new regulations. We find these regulations to be 'decisive' in spurring generic penetration significantly, with the main beneficiary being the Japanese government (or society) and not the generic companies. (http://www.bharatbook.com/biotechnology-market-research-reports/global-pharmaceutical-biotechnology-outlook-2014-japan-pharma.html)

     (Logo: http://photos.prnewswire.com/prnh/20130128/590935 )

The implications of new price-reversions are going to have many facets and will change conventional business models.  We expect many support services industries - CMOs, CROs and other allied services industries to benefit from these structural changes, while API importers will suffer.  We also expect consolidation and M&A activities to spur in Japan.

Innovation Takes the Driver's Seat:  While the new regulations will change the current business philosophy of doing business in patent expired space (>45% to total Japan market), the policy makers also discourage 'me too' innovations at the same time. The regulators however tend to support the 'first time in the world' level innovations by providing 'innovation premiums'.  Japanese innovators will now become more serious and selective in their R&D approach.  Previous year the Japanese innovators have focused on acquiring assets in - autoimmune, orphan diseases and oncology fields (Annexure 5).  We expect this trend to prevail in the coming years.  We find some of the candidates to remain in the limelight in 2014 along with some new additions - Edoxaban (Daiichi Sankyo), Invokana (Mitsubishi Tanabe), Dolutegravir (Shionogi), BBI-608 (Dainippon Sumitomo), Vedolizumab (Takeda), Xtandi (Astellas), Nivolumab (Ono) to hand-pick a few of them. The reports explain detail analysis on these key candidates.

The 138 pages report contains the detailed discussion of Japan biopharmaceutical market - which includes- Our view on the impact of 2014 price cuts on generic companies and innovator companies and detailed discussion on key attributes (consolidation activities, potential of R & D pipeline candidates, generic threat in domestic Japan market etc…) of leading Japanese innovator companies- Astellas, Chugai, Daiichi Sankyo, Dainippon Sumitomo,  Eisai, Kyorin, Kyowa hakko Kirin, Mitsubishi Tanabe, Shionogi,  Takeda and  leading Japanese generic companies- Nippon Chemiphar, Sawai and Towa.

Request for sample pages:  http://www.bharatbook.com/RequestSample.asp?pid=364878

Table of Contents

  • INNOVATORS:
  • New Price-Cuts - A Double Punch To The Innovators!
  • Table 1- New Slabs For Nhi Price Cuts For Long-listed Drugs
  • Table 2 - Expense Vs. Portability Of Japanese Innovators
  • Another Blow For Innovators In Not Institutionalizing The 'Innovation Premium'
  • GENERICS:
  • Pressure To Generic Discount Further Increased
  • Upcoming New Generics
  • Existing Generics
  • Table 3 - New Drug Prices For Existing Ge Drugs
  • Listing Of GE Drugs by Both GE Name And Brand To Promote Discounting
  • IMPLICATIONS:
  • Finding New Avenues Of Cost Saving Are Inevitable For GE Cos
  • Innovators Need To Redone Long-Listed Products Strategies
  • Consolidation Activities To Will Witness A Boost
  • Table 4 - Other REGULATION UNDER APRIL-14 REFORMS*
  • Table 5 -Portably Structure Of Select Generic Companies
  • Annexure 1 JAPAN GEnerics Market Model
  • Annexure 2 Japanese Innovators: Long Listed Exposure
  • Annexure 3 PATENT EXPIRY THROUGH 2016
  • JAPAN INNOVATORS
  • ASTELLAS: Successful Global Launch of Xtandi And Myrbetriq To Overcome Domestic worries!
  • Prograf Generics Launch in Japan
  • Xtandi
  • JP Approval ahead than Zytiga
  • What to watch out for in Detailed PREVAIL data in Late Feb at ASCO GU-14?
  • Prevail top line data of Xtandi - rPFS advantage and ease of use compensate absolute OS disappointment for urologist
  • Recent US prescription trends of Xtandi are encouraging
  • Isavuconazole: Isavuconazole QIDP designation and our expectation
  • Competitive landscape of Antifungals

For more information and complete table of contents:  http://www.bharatbook.com/biotechnology-market-research-reports/global-pharmaceutical-biotechnology-outlook-2014-japan-pharma.html

Related Reports:

Related Category:

About Bharat Book Bureau

Bharat Book Bureau is the leading market research information aggregator that provides market research reports, industry analysis, company profiles, business reports, country reports, newsletters and online databases. Our clients include Corporate, Consulting firms, and Academic Institutions and Government departments across the globe. Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. The market research reports we provide, help global companies examine the different markets before setting up a business or expanding into different countries across the world. They give a complete perspective on the current market scenario, trends, segments and future outlook.

Contact us:
Poonam
Bharat Book Bureau
USA/Canada - 1-866-279-8368 (Toll free)
India: +91-22-27810772, 27810773
Blog: http://blog.bharatbook.com
E: [email protected]
W: http://www.bharatbook.com

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at Cloud Expo, Ed Featherston, a director and senior enterprise architect at Collaborative Consulting, discussed the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
In his session at Cloud Expo, Alan Winters, U.S. Head of Business Development at MobiDev, presented a success story of an entrepreneur who has both suffered through and benefited from offshore development across multiple businesses: The smart choice, or how to select the right offshore development partner Warning signs, or how to minimize chances of making the wrong choice Collaboration, or how to establish the most effective work processes Budget control, or how to maximize project result...
"DivvyCloud as a company set out to help customers automate solutions to the most common cloud problems," noted Jeremy Snyder, VP of Business Development at DivvyCloud, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
CI/CD is conceptually straightforward, yet often technically intricate to implement since it requires time and opportunities to develop intimate understanding on not only DevOps processes and operations, but likely product integrations with multiple platforms. This session intends to bridge the gap by offering an intense learning experience while witnessing the processes and operations to build from zero to a simple, yet functional CI/CD pipeline integrated with Jenkins, Github, Docker and Azure...
"Our strategy is to focus on the hyperscale providers - AWS, Azure, and Google. Over the last year we saw that a lot of developers need to learn how to do their job in the cloud and we see this DevOps movement that we are catering to with our content," stated Alessandro Fasan, Head of Global Sales at Cloud Academy, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"Akvelon is a software development company and we also provide consultancy services to folks who are looking to scale or accelerate their engineering roadmaps," explained Jeremiah Mothersell, Marketing Manager at Akvelon, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
IoT is rapidly becoming mainstream as more and more investments are made into the platforms and technology. As this movement continues to expand and gain momentum it creates a massive wall of noise that can be difficult to sift through. Unfortunately, this inevitably makes IoT less approachable for people to get started with and can hamper efforts to integrate this key technology into your own portfolio. There are so many connected products already in place today with many hundreds more on the h...
As organizations shift towards IT-as-a-service models, the need for managing and protecting data residing across physical, virtual, and now cloud environments grows with it. Commvault can ensure protection, access and E-Discovery of your data – whether in a private cloud, a Service Provider delivered public cloud, or a hybrid cloud environment – across the heterogeneous enterprise. In his general session at 18th Cloud Expo, Randy De Meno, Chief Technologist - Windows Products and Microsoft Part...
DXWorldEXPO LLC announced today that ICC-USA, a computer systems integrator and server manufacturing company focused on developing products and product appliances, will exhibit at the 22nd International CloudEXPO | DXWorldEXPO. DXWordEXPO New York 2018, colocated with CloudEXPO New York 2018 will be held November 11-13, 2018, in New York City. ICC is a computer systems integrator and server manufacturing company focused on developing products and product appliances to meet a wide range of ...
Andi Mann, Chief Technology Advocate at Splunk, is an accomplished digital business executive with extensive global expertise as a strategist, technologist, innovator, marketer, and communicator. For over 30 years across five continents, he has built success with Fortune 500 corporations, vendors, governments, and as a leading research analyst and consultant.
JETRO showcased Japan Digital Transformation Pavilion at SYS-CON's 21st International Cloud Expo® at the Santa Clara Convention Center in Santa Clara, CA. The Japan External Trade Organization (JETRO) is a non-profit organization that provides business support services to companies expanding to Japan. With the support of JETRO's dedicated staff, clients can incorporate their business; receive visa, immigration, and HR support; find dedicated office space; identify local government subsidies; get...
René Bostic is the Technical VP of the IBM Cloud Unit in North America. Enjoying her career with IBM during the modern millennial technological era, she is an expert in cloud computing, DevOps and emerging cloud technologies such as Blockchain. Her strengths and core competencies include a proven record of accomplishments in consensus building at all levels to assess, plan, and implement enterprise and cloud computing solutions. René is a member of the Society of Women Engineers (SWE) and a m...
In this presentation, you will learn first hand what works and what doesn't while architecting and deploying OpenStack. Some of the topics will include:- best practices for creating repeatable deployments of OpenStack- multi-site considerations- how to customize OpenStack to integrate with your existing systems and security best practices.
Explosive growth in connected devices. Enormous amounts of data for collection and analysis. Critical use of data for split-second decision making and actionable information. All three are factors in making the Internet of Things a reality. Yet, any one factor would have an IT organization pondering its infrastructure strategy. How should your organization enhance its IT framework to enable an Internet of Things implementation? In his session at @ThingsExpo, James Kirkland, Red Hat's Chief Archi...
Digital transformation has increased the pace of business creating a productivity divide between the technology haves and have nots. Managing financial information on spreadsheets and piecing together insight from numerous disconnected systems is no longer an option. Rapid market changes and aggressive competition are motivating business leaders to reevaluate legacy technology investments in search of modern technologies to achieve greater agility, reduced costs and organizational efficiencies. ...